Zentalis Pharmaceuticals (ZNTL) Competitors

$2.35 -0.06 (-2.29%)

As of 01:48 PM Eastern

ZNTL vs. COLL, ZVRA, AQST, CRMD, and PHAT

Should you buy Zentalis Pharmaceuticals stock or one of its competitors? Zentalis Pharmaceuticals's main competitors and comparable companies include Collegium Pharmaceutical (COLL), Zevra Therapeutics (ZVRA), Aquestive Therapeutics (AQST), CorMedix (CRMD), and Phathom Pharmaceuticals (PHAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Collegium Pharmaceutical has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	2.55	-$137.06M	-$1.95	N/A
Collegium Pharmaceutical	$780.57M	0.90	$62.87M	$1.24	17.36

Collegium Pharmaceutical has a net margin of 5.93% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.02 beat Collegium Pharmaceutical's score of 0.15 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
Collegium Pharmaceutical	Neutral

Zentalis Pharmaceuticals currently has a consensus price target of $7.50, indicating a potential upside of 212.50%. Collegium Pharmaceutical has a consensus price target of $48.71, indicating a potential upside of 126.26%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Collegium Pharmaceutical	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Zentalis Pharmaceuticals has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Zentalis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Zevra Therapeutics had 6 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Zevra Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Zevra Therapeutics' average media sentiment score of 1.13 beat Zentalis Pharmaceuticals' score of 1.02 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Zevra Therapeutics	Positive
Zentalis Pharmaceuticals	Positive

Zevra Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	5.79	$83.23M	$0.92	11.29
Zentalis Pharmaceuticals	$67.43M	2.55	-$137.06M	-$1.95	N/A

35.0% of Zevra Therapeutics shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zevra Therapeutics currently has a consensus target price of $27.14, suggesting a potential upside of 161.24%. Zentalis Pharmaceuticals has a consensus target price of $7.50, suggesting a potential upside of 212.50%. Given Zentalis Pharmaceuticals' higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zevra Therapeutics has a net margin of 42.82% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Summary

Zevra Therapeutics beats Zentalis Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Aquestive Therapeutics?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Zentalis Pharmaceuticals presently has a consensus price target of $7.50, suggesting a potential upside of 212.50%. Aquestive Therapeutics has a consensus price target of $8.60, suggesting a potential upside of 84.15%. Given Zentalis Pharmaceuticals' higher possible upside, equities research analysts plainly believe Zentalis Pharmaceuticals is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 2 mentions for Aquestive Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.02 beat Aquestive Therapeutics' score of 0.91 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
Aquestive Therapeutics	Positive

Zentalis Pharmaceuticals has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

32.5% of Aquestive Therapeutics shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aquestive Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	2.55	-$137.06M	-$1.95	N/A
Aquestive Therapeutics	$44.54M	13.16	-$83.78M	-$0.65	N/A

Summary

Aquestive Therapeutics beats Zentalis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

CorMedix has a net margin of 40.49% compared to Zentalis Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 40.52% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

In the previous week, CorMedix and CorMedix both had 1 articles in the media. CorMedix's average media sentiment score of 1.41 beat Zentalis Pharmaceuticals' score of 1.02 indicating that CorMedix is being referred to more favorably in the media.

Company	Overall Sentiment
CorMedix	Positive
Zentalis Pharmaceuticals	Positive

CorMedix has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.85	$163.05M	$2.14	3.45
Zentalis Pharmaceuticals	$67.43M	2.55	-$137.06M	-$1.95	N/A

34.2% of CorMedix shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CorMedix has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

CorMedix currently has a consensus target price of $15.00, indicating a potential upside of 102.98%. Zentalis Pharmaceuticals has a consensus target price of $7.50, indicating a potential upside of 212.50%. Given Zentalis Pharmaceuticals' higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

CorMedix beats Zentalis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Phathom Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	2.55	-$137.06M	-$1.95	N/A
Phathom Pharmaceuticals	$175.11M	3.23	-$221.25M	-$1.28	N/A

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Zentalis Pharmaceuticals currently has a consensus price target of $7.50, indicating a potential upside of 212.50%. Phathom Pharmaceuticals has a consensus price target of $21.25, indicating a potential upside of 203.57%. Given Zentalis Pharmaceuticals' higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Phathom Pharmaceuticals had 5 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 6 mentions for Phathom Pharmaceuticals and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.02 beat Phathom Pharmaceuticals' score of 0.59 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
Phathom Pharmaceuticals	Positive

Zentalis Pharmaceuticals has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$168.07M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-1.20	807.81	275.40	25.37
Price / Sales	2.49	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.78	9.21	10.55	5.95
Net Income	-$137.06M	$2.84B	$3.50B	$380.75M
7 Day Performance	-8.04%	-4.00%	-3.92%	-3.96%
1 Month Performance	-33.00%	-8.07%	-8.30%	-6.81%
1 Year Performance	52.27%	-5.86%	2.35%	-4.58%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	3.3979 of 5 stars	$2.35 -2.3%	$7.50 +219.8%	+48.1%	$168.07M	$67.43M	N/A	106
COLL Collegium Pharmaceutical	3.9413 of 5 stars	$21.87 -0.7%	$48.71 +122.7%	-32.8%	$716.88M	$808.21M	17.64	423
ZVRA Zevra Therapeutics	4.2208 of 5 stars	$10.70 +7.1%	$27.14 +153.7%	-2.8%	$593.24M	$106.47M	11.63	61	News Coverage Insider Trade Gap Down High Trading Volume
AQST Aquestive Therapeutics	1.8783 of 5 stars	$4.57 +0.4%	$9.17 +100.6%	-29.9%	$571.08M	$54.09M	N/A	147	News Coverage
CRMD CorMedix	3.0687 of 5 stars	$7.26 +1.0%	$15.00 +106.6%	-30.2%	$560.42M	$311.71M	3.39	191	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. COLL, ZVRA, AQST, CRMD, and PHAT

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Summary

How does Zentalis Pharmaceuticals compare to Zevra Therapeutics?

Summary

How does Zentalis Pharmaceuticals compare to Aquestive Therapeutics?

Summary

How does Zentalis Pharmaceuticals compare to CorMedix?

Summary

How does Zentalis Pharmaceuticals compare to Phathom Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. COLL, ZVRA, AQST, CRMD, and PHAT

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Which has better valuation & earnings, ZNTL or COLL?

Is ZNTL or COLL more profitable?

Does the media prefer ZNTL or COLL?

Do analysts recommend ZNTL or COLL?

Which has more volatility & risk, ZNTL or COLL?

Summary

How does Zentalis Pharmaceuticals compare to Zevra Therapeutics?

Does the media prefer ZVRA or ZNTL?

Which has more risk and volatility, ZVRA or ZNTL?

Which has stronger valuation and earnings, ZVRA or ZNTL?

Do insiders & institutionals hold more shares of ZVRA or ZNTL?

Do analysts recommend ZVRA or ZNTL?

Is ZVRA or ZNTL more profitable?

Summary

How does Zentalis Pharmaceuticals compare to Aquestive Therapeutics?

Is ZNTL or AQST more profitable?

Do analysts recommend ZNTL or AQST?

Does the media prefer ZNTL or AQST?

Which has more risk & volatility, ZNTL or AQST?

Do insiders and institutionals hold more shares of ZNTL or AQST?

Which has better earnings & valuation, ZNTL or AQST?

Summary

How does Zentalis Pharmaceuticals compare to CorMedix?

Is CRMD or ZNTL more profitable?

Does the media prefer CRMD or ZNTL?

Which has stronger earnings & valuation, CRMD or ZNTL?

Do institutionals & insiders believe in CRMD or ZNTL?

Which has more volatility and risk, CRMD or ZNTL?

Do analysts rate CRMD or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Phathom Pharmaceuticals?

Which has better earnings and valuation, ZNTL or PHAT?

Do institutionals & insiders believe in ZNTL or PHAT?

Is ZNTL or PHAT more profitable?

Do analysts prefer ZNTL or PHAT?

Does the media favor ZNTL or PHAT?

Which has more volatility & risk, ZNTL or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools